Obizur
Exhibitor：Takeda Pharmaceutical Company Limited
Country (Region) of Origin：Japan
Obizur 将是国内首个用于治疗获得性血友病的猪序列重组抗血友病因子,可非常好的替代人FVIII发挥止血作用，是国际指南推荐的一线止血药物之一，为AHA患者出血治疗提供了全新的替代治疗的选择。
Exhibits of the Same Type
Exhibit Details
Obizur will be the first porcine sequence recombinant anti-hemophilia factor used in the treatment of acquired hemophilia A in China, which can be a ideal substitute for human FVIII to play a hemostatic role. Obizur is one of the first-line hemostatic drugs recommended by international guidelines, and provides a new alternative treatment option for the bleeding treatment of AHA patients.